Summary

In the open-label, phase 3 RE-VERSE AD trial, idarucizumab resulted in complete reversal of dabigatran-related anticoagulation in up to 88% of patients with uncontrolled bleeding or who required an emergent procedure, with no safety concerns. The median maximum reversal of 100% occurred within 4 hours and was evident within minutes after the first of 2 idarucizumab infusions.